Scholarlink

Background <p>Numerous studies in the field of cancer indicate that long non-coding RNAs (lncRNAs) play a significant role in the development and malignancy of various cancers. In this study, the expression changes of <i>TMEM105</i> in gastric cancer (GC) and its association with malignancy were examined.</p> Methods <p>In the in silico section, <i>TMEM105</i> expression in GC and its correlation with patient prognosis were analyzed using publicly available datasets. Using WGCNA analysis on TCGA data, modules and potential pathways associated with <i>TMEM105</i> were identified. Expression changes of <i>TMEM105</i> in GC tissues compared with adjacent healthy tissues were analyzed by RT-qPCR. The expression level of <i>TMEM105</i> in GC cell lines, including AGS and MKN-45, was modulated using siRNA. The relationship between <i>TMEM105</i> expression and malignant characteristics, including cell proliferation, migration, and colony formation, was examined in these cell lines.</p> Results <p><i>TMEM105</i> was significantly upregulated in public datasets, including TCGA, GSE19826, and GSE54129. <i>TMEM105</i> expression was associated with advanced disease stage and poor prognosis. WGCNA analysis revealed that <i>TMEM105</i> expression clustered with genes related to cell proliferation, such as E2F target genes, within the same module. Silencing <i>TMEM105</i> reduced the viability of GC cell lines and decreased mRNA expression of proliferation-related genes, including <i>E2F1</i>, <i>Cyclin D1</i>, and <i>Ki-67</i>. Silencing <i>TMEM105</i> markedly reduced migration rates in GC cells. Moreover, <i>TMEM105</i> expression affected the colony-forming ability of these cell lines.</p> Conclusion <p>High <i>TMEM105</i> expression in GC is associated with poorer patient outcomes. It appears to influence cellular proliferation and contribute to the development and malignancy of gastric carcinoma. Consequently, <i>TMEM105</i> could be a valuable therapeutic and prognostic target.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Silencing TMEM105 suppresses gastric cancer cell growth and migration via proliferation-associated pathways

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月30日

查看全文
  • Behnoosh Nikonezhad,
  • Mobina Shahriarizade,
  • Atefeh Zamani,
  • Mohammad Mahdevar

摘要

Background

Numerous studies in the field of cancer indicate that long non-coding RNAs (lncRNAs) play a significant role in the development and malignancy of various cancers. In this study, the expression changes of TMEM105 in gastric cancer (GC) and its association with malignancy were examined.

Methods

In the in silico section, TMEM105 expression in GC and its correlation with patient prognosis were analyzed using publicly available datasets. Using WGCNA analysis on TCGA data, modules and potential pathways associated with TMEM105 were identified. Expression changes of TMEM105 in GC tissues compared with adjacent healthy tissues were analyzed by RT-qPCR. The expression level of TMEM105 in GC cell lines, including AGS and MKN-45, was modulated using siRNA. The relationship between TMEM105 expression and malignant characteristics, including cell proliferation, migration, and colony formation, was examined in these cell lines.

Results

TMEM105 was significantly upregulated in public datasets, including TCGA, GSE19826, and GSE54129. TMEM105 expression was associated with advanced disease stage and poor prognosis. WGCNA analysis revealed that TMEM105 expression clustered with genes related to cell proliferation, such as E2F target genes, within the same module. Silencing TMEM105 reduced the viability of GC cell lines and decreased mRNA expression of proliferation-related genes, including E2F1, Cyclin D1, and Ki-67. Silencing TMEM105 markedly reduced migration rates in GC cells. Moreover, TMEM105 expression affected the colony-forming ability of these cell lines.

Conclusion

High TMEM105 expression in GC is associated with poorer patient outcomes. It appears to influence cellular proliferation and contribute to the development and malignancy of gastric carcinoma. Consequently, TMEM105 could be a valuable therapeutic and prognostic target.